Primary haemorrhage during myomectomy
Conditions
Interventions
vaginal misoprostol plus pericervicl tourniquet
Sponsors
Deliverance Agyabeng
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: All reproductive-aged women with symptomatic fibroids who desire future fertility Uterine size not exceeding 28 weeks gestation on abdominal examination All women with symptomatic uterine fibroids who give voluntary consent tp partake in the study
Exclusion criteria
Exclusion criteria: Parous reproductive-aged women with symptomatic fibroids and no future fertility wishes Peri-menopausal women with symptomatic fibroids who do not desire fertility Women with hemoglobin level less than 10g/dl before surgery Women with prior abdominal surgeries including Cesarean section and previous myomectomy Women with body mass index greater than 35kg/m2, due to surgical challenges Women who refuse blood transfusion Women with hemoglobinopathies and coagulation disorders Women with co-existing chronic medical conditions Women who have allergies to prostaglandins Women with symptoms suggestive of Covid-19 and who test positive for the virus within two weeks prior to surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the reduction in blood loss using pre-operative and post-operative hemoglobin changes between women in the treatment and control groups | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine the need for intraoperative or post-operative blood transfusion for women in both the treatment and the control groups. To assess the prevalence of adverse effects of misoprostol in the treatment group. To assess the differences in post-operative febrile morbidity, surgery duration and length of hospital stay in both the treatment and control groups | — |
Countries
Ghana
Contacts
Public ContactPrince Ashitey
Administration officer
Outcome results
None listed